# OnCo record kartos-therapeutics (company). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/companies/kartos-therapeutics/>
  a schema:Organization ;
  onco:kind "company" ;
  schema:identifier "kartos-therapeutics" ;
  schema:name "Kartos Therapeutics"@en ;
  schema:alternateName "Kartos Therapeutics, Inc."@en ;
  schema:description "Kartos Therapeutics is a United States-based biotechnology company running 3 late-stage cancer trials of KRT-232 and Ruxolitinib in myeloproliferative neoplasms, endometrial cancer and diffuse large B-cell lymphoma."@en ;
  schema:url <https://onco.cc/companies/kartos-therapeutics/>, <https://www.kartosthera.com> ;
  schema:dateModified "2026-09-11"^^xsd:date ;
  schema:citation <https://www.kartosthera.com>, <https://clinicaltrials.gov/search?lead=Kartos%20Therapeutics%2C%20Inc.> ;
  onco:tag "ctgov-sponsor" ;
  schema:addressCountry "US" ;
  onco:cancers <https://onco.cc/cancers/myeloproliferative-neoplasms/>, <https://onco.cc/cancers/endometrial/>, <https://onco.cc/cancers/dlbcl/>, <https://onco.cc/cancers/cll/>, <https://onco.cc/cancers/hodgkin-lymphoma/> ;
  onco:drugs <https://onco.cc/drugs/krt-232/> ;
  onco:trials <https://onco.cc/trials/nct05797831/>, <https://onco.cc/trials/nct04502394/>, <https://onco.cc/trials/nct03669965/> .